bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
â–²(210.08% Upside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (widening losses, revenue contraction, and rising cash burn despite improved leverage). Technicals are moderately supportive with positive momentum but appear overbought, while corporate updates are positive (studies, validation efforts, and clinician engagement) but remain early-stage relative to the current cash-flow profile.
Positive Factors
Large-scale clinical study
A 2,000-patient, multi-site longitudinal trial builds durable clinical evidence and external validation, which are essential for shifting a diagnostic from niche use to guideline inclusion. Robust real-world data can materially improve clinician adoption, payer coverage discussions, and long-term market access.
Negative Factors
Negative operating cash flow
Persistent negative operating and free cash flow forces dependence on external financing, which can dilute shareholders and constrain product commercialization. Until cash generation turns positive, the company faces heightened funding risk that limits investments in sales, reimbursement efforts, and study scaling.
Read all positive and negative factors
Positive Factors
Negative Factors
Large-scale clinical study
A 2,000-patient, multi-site longitudinal trial builds durable clinical evidence and external validation, which are essential for shifting a diagnostic from niche use to guideline inclusion. Robust real-world data can materially improve clinician adoption, payer coverage discussions, and long-term market access.
Read all positive factors
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.99M
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)-3.74
Revenue Growth-27.66%
EPS Growth13.18%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)5.98
Shares Outstanding4,498,675
10 Day Avg. Volume6,249,809
30 Day Avg. Volume5,911,951
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.33
P/FCF Ratio-0.22
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit8.88
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.1
Revenue Forecast (FY)$7.31M
bioAffinity Technologies, Inc. Business Overview & Revenue Model
Company Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researche...
How the Company Makes Money
bioAffinity Technologies makes money primarily by commercializing and selling its diagnostic testing offerings, led by CyPath® Lung. Revenue is expected to be generated through fees for testing and related diagnostic services (e.g., payments recei...
bioAffinity Technologies, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
52
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.16M | 9.36M | 2.53M | 4.80K | 0.00 |
| Gross Profit | 1.43M | 3.38M | 791.62K | 4.34K | -4.82K |
| EBITDA | -10.07M | -8.33M | -7.63M | -5.61M | -5.32M |
| Net Income | -14.91M | -9.04M | -7.94M | -8.15M | -6.33M |
Balance Sheet | |||||
| Total Assets | 10.96M | 6.51M | 8.22M | 12.18M | 1.45M |
| Cash, Cash Equivalents and Short-Term Investments | 6.45M | 1.11M | 2.82M | 11.41M | 1.36M |
| Total Debt | 1.16M | 1.50M | 1.58M | 251.75K | 11.36M |
| Total Liabilities | 3.68M | 3.91M | 3.37M | 1.14M | 17.24M |
| Stockholders Equity | 7.28M | 2.60M | 4.86M | 11.04M | -15.79M |
Cash Flow | |||||
| Free Cash Flow | -9.39M | -7.34M | -6.06M | -4.29M | -2.05M |
| Operating Cash Flow | -9.33M | -7.26M | -6.04M | -4.07M | -2.05M |
| Investing Cash Flow | -60.57K | -79.08K | -2.21M | -219.99K | 0.00 |
| Financing Cash Flow | 14.73M | 5.63M | -344.98K | 14.34M | 3.33M |
bioAffinity Technologies, Inc. Technical Analysis
Positive
1.29
Price Trends
1.59
Positive
1.56
Positive
4.17
Negative
Market Momentum
0.82
Negative
64.76
Neutral
67.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Positive. The current price of 1.29 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 1.59, and below the 200-day MA of 4.17, indicating a neutral trend. The MACD of 0.82 indicates Negative momentum. The RSI at 64.76 is Neutral, neither overbought nor oversold. The STOCH value of 67.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIAF.
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. disclosed 83 risk factors in its most recent earnings report. bioAffinity Technologies, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
bioAffinity Technologies, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $17.99M | -0.16 | -245.18% | ― | -27.66% | 13.18% | |
44 Neutral | $6.44M | -0.85 | -197.93% | ― | 3.26% | 65.96% | |
42 Neutral | $5.07M | -0.64 | -537.60% | ― | ― | 98.86% | |
41 Neutral | $1.43M | -0.68 | -296.20% | ― | -67.73% | 58.35% |
* Healthcare Sector Average
BIAF
bioAffinity Technologies, Inc.
4.00
-3.80
-48.72%
NDRA
ENDRA Life Sciences
4.35
0.25
6.10%
INBS
Intelligent Bio Solutions
3.22
-11.18
-77.64%
ISPC
iSpecimen
0.15
-0.91
-86.23%
BGLC
BioNexus Gene Lab Corp
2.35
-0.01
-0.51%
bioAffinity Technologies, Inc. Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
bioAffinity Technologies Posts New Investor Presentation Materials
Neutral
Mar 26, 2026
bioAffinity Technologies, Inc., a Delaware corporation, reported that it has prepared a set of presentation materials covering its operations and performance for use by management in investor and stakeholder presentations. These materials were pos...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches Virtual Roundtables on CyPath Lung Adoption
Positive
Mar 25, 2026
On March 25, 2026, bioAffinity Technologies announced it will host the first in a series of live virtual physician roundtables exploring the integration of its CyPath® Lung diagnostic test into pulmonary practice. The inaugural session, sched...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Showcases CyPath Lung Case Study in Diagnostics
Positive
Mar 17, 2026
bioAffinity Technologies, Inc., a biotechnology company specializing in noninvasive lung cancer diagnostics, on March 17, 2026 released a clinical case study on its CyPath® Lung test. CyPath® Lung uses flow cytometry, artificial intellig...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches Major Lung Cancer Detection Study
Positive
Mar 10, 2026
On March 10, 2026, bioAffinity Technologies announced the start of a 2,000-patient, large-scale longitudinal clinical study to evaluate the clinical performance of its CyPath® Lung technology for early detection of lung cancer in high-risk in...
Executive/Board ChangesShareholder Meetings
bioAffinity Announces Upcoming Departure of Two Board Directors
Neutral
Mar 6, 2026
bioAffinity Technologies, Inc. disclosed that on March 5, 2026, directors Robert Anderson and Roby Joyce informed the Board they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders, scheduled for ...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care
Positive
Mar 4, 2026
On March 1, 2026, bioAffinity Technologies presented new research at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia showing its sputum-based diagnostic platform can identify antibody drug receptors for leadin...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches New CyPath Lung Validation Study
Positive
Feb 25, 2026
On February 25, 2026, bioAffinity Technologies announced a new validation study with Brooke Army Medical Center to test the clinical utility of its CyPath® Lung diagnostic on sputum samples obtained via tracheal and bronchial suctioning. The ...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Highlights CyPath Lung Case Study in Diagnostics
Positive
Feb 19, 2026
On February 19, 2026, bioAffinity Technologies released a clinical case study showing how its CyPath® Lung noninvasive diagnostic test guided treatment for a 79-year-old woman whose June 2025 low-dose CT scan revealed a suspicious spiculated ...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Highlights CyPath Lung Clinical Utility in Surveillance
Positive
Feb 17, 2026
On February 17, 2026, bioAffinity Technologies reported a real-world clinical case study in which its CyPath® Lung test aided management of a 59-year-old high-risk smoker with multiple small pulmonary nodules categorized as probably benign. T...
Business Operations and StrategyRegulatory Filings and Compliance
bioAffinity Technologies Updates Investor Presentation Materials Online
Neutral
Feb 10, 2026
On February 10, 2026, bioAffinity Technologies, Inc. posted new presentation materials to its website that management plans to use periodically to discuss the company’s operations and performance with investors and other audiences. The mater...
Business Operations and StrategyExecutive/Board Changes
bioAffinity Adds Leading Lung Cancer Experts to Advisory Board
Positive
Feb 9, 2026
On February 9, 2026, bioAffinity Technologies appointed three nationally recognized pulmonary and lung cancer specialists — David Ost of MD Anderson Cancer Center, Daniel Sterman of NYU Langone Health, and J. Scott Ferguson of the University...
Business Operations and StrategyShareholder Meetings
bioAffinity Sets 2026 Annual Meeting, Revives Prior Proposals
Neutral
Feb 4, 2026
bioAffinity Technologies scheduled its 2026 annual stockholder meeting for April 30, 2026 in San Antonio after an adjourned December 19, 2025 special meeting lacked quorum, and it will carry forward those proposals while requiring shareholder nomi...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
bioAffinity Labs Maintain CAP Accreditation, Supporting CyPath Lung
Positive
Jan 7, 2026
On January 7, 2026, bioAffinity Technologies announced that its subsidiary Precision Pathology Laboratory Services in San Antonio successfully maintained its accreditation from the College of American Pathologists following a rigorous on-site insp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.